Melio Bio is an innovative, early-stage biotechnology company dedicated to the discovery and development of novel therapeutics for obesity and associated cardiometabolic diseases.

Co-created with Molecule to Medicine (MTM), Melio Bio leverages human genetics and advanced drug discovery expertise to target pathways that promise safer and better-tolerated therapeutic options. Our mission is to deliver new medicines that effectively reduce fat mass while preserving healthy muscle, ultimately improving the lives of patients and promoting healthy metabolic fitness globally.

As a company focused on genetically validated targets, Melio Bio is poised to bring breakthroughs to an area of significant unmet medical need.